- Home
- EONR vs HOOK Comparison
EONR vs HOOK Comparison
Compare EONR & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- HOOK
- Stock Information
- Founded
- EONR 2017
- HOOK 2011
- Country
- EONR United States
- HOOK United States
- Employees
- EONR N/A
- HOOK N/A
- Industry
- EONR
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- HOOK Health Care
- Exchange
- EONR NYSE
- HOOK Nasdaq
- Market Cap
- EONR 7.8M
- HOOK 9.3M
- IPO Year
- EONR N/A
- HOOK 2019
- Fundamental
- Price
- EONR $0.39
- HOOK $1.44
- Analyst Decision
- EONR Strong Buy
- HOOK Buy
- Analyst Count
- EONR 1
- HOOK 4
- Target Price
- EONR $4.50
- HOOK $10.67
- AVG Volume (30 Days)
- EONR 317.4K
- HOOK 148.4K
- Earning Date
- EONR 05-23-2025
- HOOK 05-27-2025
- Dividend Yield
- EONR N/A
- HOOK N/A
- EPS Growth
- EONR N/A
- HOOK N/A
- EPS
- EONR N/A
- HOOK N/A
- Revenue
- EONR $20,269,293.00
- HOOK $43,946,000.00
- Revenue This Year
- EONR $46.94
- HOOK N/A
- Revenue Next Year
- EONR $64.38
- HOOK N/A
- P/E Ratio
- EONR N/A
- HOOK N/A
- Revenue Growth
- EONR N/A
- HOOK 118.32
- 52 Week Low
- EONR $0.35
- HOOK $0.72
- 52 Week High
- EONR $3.15
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- HOOK 61.47
- Support Level
- EONR N/A
- HOOK $1.22
- Resistance Level
- EONR N/A
- HOOK $1.47
- Average True Range (ATR)
- EONR 0.00
- HOOK 0.19
- MACD
- EONR 0.00
- HOOK 0.03
- Stochastic Oscillator
- EONR 0.00
- HOOK 69.36
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.